A Phase 2 Multicohort Study to Evaluate Lorigerlimab in Participants With Advanced Solid Tumors
Latest Information Update: 20 Dec 2024
Price :
$35 *
At a glance
- Drugs Lorigerlimab (Primary)
- Indications Cervical cancer; Endometrial cancer; Fallopian tube cancer; Ovarian cancer; Peritoneal cancer; Solid tumours
- Focus Therapeutic Use
- Sponsors MacroGenics
- 20 Dec 2024 New trial record